#45 – Pfizer vs. the White House: Inside the Deal That Changed Drug Pricing

The recent drug-pricing clash between Pfizer and the Trump administration wasn't just another policy fight – it was a huge negotiation in US healthcare. This was a high-wire act: a pharmaceutical giant under intense political pressure, a White House eager for a headline win, and billions of dollars on the line. This week on S4N, Gene breaks down how Pfizer held its ground, built quiet alliances, and seized the exact moment the Trump administration started negotiating against itself. Most importantly, he explains the critical difference between power and influence — and when to use each. Pfizer's moves weren't luck – they were deliberate, and they offer a rare look into how power and influence operate when the stakes are national. Gene connects the dots between this negotiation and the kinds of decisions executives face every day: knowing when to hold, when to move, and how to shape the field before the other side does. For anyone who deals in high-stakes conversations – inside healthcare or out – this isn't just history. It's a list of strategies. Remember: negotiation is life. Mentioned in this episode: The Best Care for Those with the Least: An Empowering Guide to Bridge the Socioeconomic Gap in Medical Care by Kristen Davis-Coelho, PhD "Inside Pfizer's Drug-Pricing Deal With the Trump Administration",  the October 2, 2025 Wall Street Journal article by Liz Essley Whyte, Jonathan D. Rockoff, and Peter Loftus